Scalable Testing for Respiratory Viral RNA Detection

The SARS-CoV-2 pandemic has created an enormous challenge for laboratories and communities worldwide. With the arrival of flu season, labs are facing unprecedented demands for respiratory viral testing. To address this ongoing crisis, labs require reliable and efficient methods to detect and differentiate between SARS-CoV-2, influenza A, and influenza B viral RNA.

Current detection methods are either too expensive or are constrained by the number of samples that can be processed daily. To meet these challenges, Agena Bioscience^® has developed the MassARRAY^® SARS-CoV-2 Panel and the MassARRAY SARS-CoV-2/Flu Panel. These panels enable accurate, high-throughput, and low-cost detection of SARS-CoV-2 and influenza.

• MAXIMIZE THROUGHPUT – Process up to thousands of samples in a workday with a single MassARRAY System.
• ENSURE ACCURATE DETECTION – Robust assay design with multiple SARS-CoV-2 targets and pan-assays for influenza A and influenza B.
• SAVE TIME & MONEY – Low-cost reagents and automated results reporting saves lab resources.
• SECURE RELIABLE SUPPLY – Immediate availability of instruments and reagents.

Get Started Now

The MassARRAY SARS-CoV-2/Flu Panel is available for Research Use Only. The MassARRAY SARS-CoV-2 Panel is available for in vitro diagnostic use under Emergency Use Authorization (EUA) from the U.S. FDA and is CE-IVD marked in Europe. For other regions, please visit our Research Use Only Panel.